Isoniazid + Rifampicin Suppliers & Bulk Manufacturers
Available Forms: Capsules / Tablet
Available Strengths: 300mg+150mg, 100mg+150mg
Reference Brands: Rifamate (USA), IsonaRif (USA), Rifinah(UK)
Category:
Antibiotics
Isoniazid + Rifampicin is a fixed-dose antitubercular antibiotic combination used for the treatment and prevention of tuberculosis (TB). It works by inhibiting bacterial cell wall synthesis (isoniazid) and blocking RNA transcription (rifampicin), providing a synergistic effect and reducing the risk of drug resistance.
Isoniazid + Rifampicin is available in Capsules / Tablet
and strengths such as 300mg+150mg, 100mg+150mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Isoniazid + Rifampicin is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Isoniazid + Rifampicin can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Isoniazid + Rifampicin, also referred to as Isoniazid + Rifampin, is a fixed-dose combination medication used for the treatment of tuberculosis (TB). This combination contains two potent first-line antitubercular agents: Isoniazid, which inhibits mycolic acid synthesis in the mycobacterial cell wall, and Rifampicin, which blocks bacterial RNA transcription. Together, they provide synergistic bactericidal activity, making the combination highly effective against Mycobacterium tuberculosis.
The medication is designed for oral administration and is commonly used alongside other antituberculosis drugs as part of a multidrug regimen to enhance efficacy and prevent drug resistance. Available in both tablet and syrup formulations, Isoniazid + Rifampicin allows for flexible dosing in adults and pediatric patients. Its fixed-dose combination simplifies therapy, ensures adherence, and supports consistent therapeutic outcomes. With a well-established safety profile and proven effectiveness, Isoniazid + Rifampicin remains a cornerstone in global TB management strategies.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing